Patents by Inventor Robert H. Purcell
Robert H. Purcell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9181530Abstract: The invention relates to the discovery of an HEV strain from a chronically infected patient. The virus grow unusually well in numerous cell cultures. Thus, the invention provides cell cultures, vectors, and vaccine compositions based on the virus. The invention relates, in part, on the identification of a new strain of HEV genotype 3 virus. Strain Kernow-C1 (genotype 3) of HEV, which was isolated from a chronically infected patient, was used to identify human, pig and deer cell lines permissive for infection. Adaptation of the Kernow-C 1 strain to growth in human hepatoma cells selected for a rare virus recombinant that contained an insertion of 174 ribonucleotides (58 amino acids) of a human ribosomal protein gene and additional mutations.Type: GrantFiled: January 10, 2012Date of Patent: November 10, 2015Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Royal Cornwall Hospital TrustInventors: Suzanne U. Emerson, Priyanka Shukla, Hanh T. Nguyen, Robert H. Purcell, Harry R. Dalton, Richard Bendall
-
Publication number: 20150252098Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: March 19, 2015Publication date: September 10, 2015Inventors: Zhaochun CHEN, Patricia EARL, Bernard MOSS, Suzanne U. EMERSON, Robert H. PURCELL
-
Patent number: 8999336Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: January 16, 2013Date of Patent: April 7, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhaochun Chen, Patricia Earl, Bernard Moss, Suzanne U. Emerson, Robert H. Purcell
-
Patent number: 8961975Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: September 19, 2013Date of Patent: February 24, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri
-
Publication number: 20150017153Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: September 19, 2013Publication date: January 15, 2015Inventors: Zhaochun CHEN, Robert H. PURCELL, Suzanne U. EMERSON, Stephen H. LEPPLA, Mahtab MOAYERI
-
Publication number: 20140227257Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: February 14, 2014Publication date: August 14, 2014Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhaochun CHEN, Stephen H. LEPPLA, Mahtab MOAYERI, Suzanne U. EMERSON, Robert H. PURCELL
-
Patent number: 8685396Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: December 21, 2005Date of Patent: April 1, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhaochun Chen, Stephen Leppla, Mahtab Moayeri, Suzanne U. Emerson, Robert H. Purcell
-
Publication number: 20130344058Abstract: The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (Fc?R) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the Fc region and related nucleic acids, vectors, host cells and methods of producing the variant and methods for preventing or treating a disorder in a mammal.Type: ApplicationFiled: December 20, 2012Publication date: December 26, 2013Applicant: The U.S. as represented by the Secretary, Department of Health & Human ServicesInventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai
-
Publication number: 20130302790Abstract: The invention relates to the discovery of an HEV strain from a chronically infected patient. The virus grow unusually well in numerous cell cultures. Thus, the invention provides cell cultures, vectors, and vaccine compositions based on the virus. The invention relates, in part, on the identification of a new strain of HEV genotype 3 virus. Strain Kernow-C1 (genotype 3) of HEV, which was isolated from a chronically infected patient, was used to identify human, pig and deer cell lines permissive for infection. Adaptation of the Kernow-C 1 strain to growth in human hepatoma cells selected for a rare virus recombinant that contained an insertion of 174 ribonucleotides (58 amino acids) of a human ribosomal protein gene and additional mutations.Type: ApplicationFiled: January 10, 2012Publication date: November 14, 2013Applicants: Royal Cornwall Hospital Trust, The Government of the United States of America, as represented by the Secretary, Department of HealtInventors: Suzanne U. Emerson, Priyanka Shukla, Hanh T. Nguyen, Robert H. Purcell, Harry R. Dalton, Richard Bendall
-
Publication number: 20130295090Abstract: Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies.Type: ApplicationFiled: July 12, 2013Publication date: November 7, 2013Inventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai
-
Patent number: 8574853Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: December 2, 2011Date of Patent: November 5, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri
-
Publication number: 20130287787Abstract: The present disclosure relates to monoclonal antibodies that bind poly-?-D-glutamic acid (?DPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.Type: ApplicationFiled: July 5, 2013Publication date: October 31, 2013Inventors: Zhaochun Chen, Robert H. Purcell, Rachel Schneerson, Joanna Kubler-Kielb, Lily Z. Dai
-
Patent number: 8506961Abstract: Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies.Type: GrantFiled: April 10, 2009Date of Patent: August 13, 2013Assignee: The United States of America as Represented by the Secretary Department of Health and Human ServicesInventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai
-
Patent number: 8501182Abstract: The present disclosure relates to monoclonal antibodies that bind poly-?-D-glutamic acid (?DPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.Type: GrantFiled: November 19, 2009Date of Patent: August 6, 2013Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human ServicesInventors: Zhaochun Chen, Robert H. Purcell, Rachel Schneerson, Joanna Kubler-Kielb, Lily Z. Dai
-
Patent number: 8404818Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: March 2, 2011Date of Patent: March 26, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhaochun Chen, Patricia Earl, Bernard Moss, Suzanne U. Emerson, Robert H. Purcell
-
Patent number: 8337854Abstract: The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (Fc?R) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the Fc region and related nucleic acids, vectors, host cells and methods of producing the variant and methods for preventing or treating a disorder in a mammal.Type: GrantFiled: April 3, 2008Date of Patent: December 25, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai
-
Patent number: 8337853Abstract: The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: October 27, 2009Date of Patent: December 25, 2012Assignee: The United States of America as represented by the Secretary, Department of Health & Human ServicesInventors: Ching-Juh Lai, Robert H. Purcell
-
Publication number: 20120171196Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: December 2, 2011Publication date: July 5, 2012Applicant: The United States of America as represented by the Secretary, Department of Health & Human ServicesInventors: Zhaochun CHEN, Robert H. PURCELL, Suzanne U. EMERSON, Stephen H. LEPPLA, Mahtab MOAYERI
-
Patent number: 8071100Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: February 21, 2008Date of Patent: December 6, 2011Assignee: The Unites States of America as represented by the Secretary of Department of Health and Human ServicesInventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri
-
Publication number: 20110243840Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: March 2, 2011Publication date: October 6, 2011Applicants: Department of Health and Human ServicesInventors: Zhaochun Chen, Patricia Earl, Bernard Moss, Suzanne U. Emerson, Robert H. Purcell